the Pepen	ork.	Reduction	Act at 1	195. no 6	ersons are	required to	гевропа (о н сош	STON DI INDON			a valid OMB control numb	151		
Substit	hute fo	ır form 14	49A/PTC)					Complet	e If Kno	Wn			
							Application	n Number	10/69	636,001				
INF	OF	TAMS	ION	DIS	CLOS	URE	Filing Dat	First Namexi Inventor STR0 Group Art Unit 1626 Examiner Name GRA			-07-2009 TROBEL			
ST	AT	EMEI	NT B	Y AF	PLIC	ANT	First Nam							
•							Group Art					_		
	(UI	e as ma	ny she	ets as n	ecessary)		Examiner					_		
Sheet		1		of		1	Altomey D	ocket Numb	per DEA	V2002/0	058 - US - NP	_		
						U.S. P	ATENT DOCU	1			Pages, Columns, Lines,			
Exeminer (Cibe	U.S.	Patent Do	Mamuse ShaD balk	Nam		ee or Applicant	Date of Pul			Where Relevent Passages or Relevant			
	1.d	Numb	O.P	(it imoun)		of Cited D	ocument	MM-DD			Figures Appear			
1/6		200300			STRO8	EL.		03-20	2003					
		200400	92513		STROB	EL		05-13				_		
20040110808 STROBEL					06-10									
N/A		200402	25013		STROB	EL		11-11-						
NA		200501	01599		ZEIHEF	3		05-12				_		
Na		6,759,4	12		STROB	EL		07-08						
Mb		6,949,5	56		STROB	EL		09-27				-		
718h		6,617,3	59		STROB			09-09				_		
NY		8,812,2	58		STROE				-2004			_		
16		200500	54729		STROE	EL		03-20	-2003			_		
		<u> </u>		_	 							_		
	_				+									
								+						
					 -			+			•			
								+			•			
					+			+						
		 		-	+									
		 			+									
		-		- -	+							_		
		•												
						FOREIG	N PATENT DO	CUMENT	•		Pages, Columns, Lines,	_		
	Cite No.1	Office ³		n <u>Palent</u> umber ⁴		i Codel (nown)	Name of Pate Applicant of Citod		Date of Pub Cited Do: MM-DD-	rument	Where Relevant Pessages of Relevant Floures Appear	1		
											<u> </u>	+		
		↓										十		
		┼┼										I		
											<u> </u>	+		
						╀╌┼╌			 			士		
		1										Į		
									 			+		
														
Examin	er	1/	r Usee		0 /				ate		1,100			
Signatu		A/	11		V_{Λ}		7 . S		Considered	リーイ	11106			

Burden Mour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the noods of the individual case. Any comments on the arrount of time you are required to complete this form should be said to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique obtains designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-tetler code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emparer must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant to to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →	1
---	---

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 2

Complet if Known						
Application Number	10/636,001					
Filing Date	August 7, 2003					
First Named Inventor	STROBEL, et al.					
Group Art Unit						
Examiner Name						
Attorney Docket Number	DEAV2002/0058 - US - NP	_				

				U.S. PATENT DOCL	JMENTS	
Examiner Cite		U.S. Patent		Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant
Initials	No.1	Number	Kind Code ² (if known)	of Cited Document	MM-DD-YYYY	Figures Appear
Ma		3,192,229		BIEL	06-29-1965	
112		4,614,810		Georgiev, et al.	10-30-1986	
1/0		5,945,431		HAOLUN, et al.	08-31-1999	
O'YE		6,008,240		PHILLIPS, et al.	12-28-1999	
						
L		<u> </u>				
	ļ	 				
L	└					
<u> </u>						
	├	 				
	┼					
	+-					
<u> </u>	\leftarrow					
	+	+				

	_	-		FOR	EIGN PATENT DOCUMEN	rs		
Examiner Initials	Cite No.1	Office	Foreign Patent Do	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
4/0		EP	0237028	Ai	VASSIL, et ai.	09-16-1987		1
4/2		wo	02/064146	AL	STROBEL, et al.	08-22-2002		↓_
/K2	,	wo	02/064545	AI	STROBEL, et al.	08-22-2002		┿
		wo	02/064546	N2	STROBEL, et al.	08-22-2002		┿
		wo	02/064565	AI	STROBEL et al.	08-22-2002		—
	_	wo	WO00/03746	AQ	LIAO	01-27-2000		4-
		wo	WQ02/20530	AL	BARTLETT, et al.	03-14-2002		—
100	-	wo	WO98/36749	Al	AHMAD, et al.	08-27-1998		┵
	 	wo	WO99/47153	Aa	LIAO	09-23-1999		+-
		1			•			_

	Date	//	
Examiner //	Considered	3///0/	
Signature / Ween		0111-18	
	 DED 600 Drow line thr	augh citation if not in conformance	e and

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->	1
--	---

PTO/SB/08B (10-95)

Please type a plus sign (+) inside this box

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of Sheet

Compl t if Kn wn						
Application Number	10/636,001					
Filing Date	August 7, 2003					
First Named Inventor	STROBEL, et al.					
Group Art Unit						
Examiner Name						
Attorney Docket Number	DEAV2002/0058 - US - NP					

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
xaminer nitlals	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
No		AGGARWAL, et al., Catalytic Cyclopropanation Of Alkenes Using Diazo Compounds Generated In Situ. A Novel Route To 2-Arylcyclopropylamines, Org. Letters, 2001, 3 (17) 2785-2788	
No		BROWN, et al., Organoboranes For Synthesis 7. An Improved General Synthesis of Primary Amines From Alkenes via Hydroboration-Organoborane Chemistry, Terahedron, 1987, 43 (18), 4071-4078	
		COUTTS, et al., Neurochemical and Neuropharmacological Properties of 4-Fluorotranylcypromine, Cell. Mol. Neurobiol., 1987, 7 (3), 271-291	
		ENDRES, et al., Stroke Protection By 3-hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors Mediated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 1998, 95, 8880-8885	
		LI, et al., Activation Of Protein Kinase Ca and or e Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, 53, 630-637	
JIG.		MOROI, et al., Interaction Of Genetic Deficiency Of Endothelial Nitric Oxide, Gender, and Pregnancy In Vascular Response To Injury In Mice, J. Clin. Invest., 1998, 101 (6), 1225-1232	
Ma		NAKAYAMA, et al., T-786- C Mutation in the 5'-Flanking Region Of The Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Circulation, 1999, 99, 2864-2870	_
N.		SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research, 1994, 74, 349-353	
N	,	VARENNE, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 2000, 11, 1329-1339	
J/{	2	WIEHL, et al., Synthese Und Absolute Konfiguration 2-Substitulerter Cyclopentanamine, Chem. Ber. 1986, 119, 2668-2677	
			_

	0			7		
Examiner	N/n a		Date Considered	3/1	106	
Signature d	14geans				7	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English tanguage Translation is attached.